Targeting the ACE2 receptor using nanomedicine: Novel approach to lung cancer therapy

The angiotensin-converting enzyme 2 (ACE2) receptor gained prominence in 2020, having been identified as a prime for entry of the novel coronavirus COVID-19, which has led to current global pandemic. Many studies have reported that lung cancer patients higher risk contracting COVID-19 due up-regulated expression ACE2 cells. Lung is heterogeneous disease and most frequently occurring globally. It more prevalent men than women accounts an estimated 40% cases. Over years, many on cancer. Conventional methods currently available detection treatment face numerous challenges. Nanomedicine risen challenges facing therapy drug delivery. With array nano delivery systems available, nanomedicine can be used develop alternative help overcome these improve therapeutic efficiency therapy. Hence, this review focuses cancer, receptor, use formulating targeted strategy directed at receptor. This may serve stepping stone exploring further targeting strategies therapies.